dilluns, 29 d’octubre del 2018

Genentech touts data for refillable eye implant in wet-AMD trial

Genentech PDS implantRoche‘s (OTC:RHHBYGenentech touted additional positive data last week from a Phase II study of its Port Delivery System, a refillable eye implant designed to deliver ranibizumab to treat wet age-related macular degeneration.

The company first reported top-line results from the Phase II Ladder study in July. The implant is intended to allow wet-AMD patients to go for months without needing to see an ophthalmologist for treatment; the current standard of care for wet-AMD patients involves monthly injections of therapy.

Get the full story at our sister site, Drug Delivery Business News.

The post Genentech touts data for refillable eye implant in wet-AMD trial appeared first on MassDevice.



from MassDevice https://ift.tt/2qgIfA1

Cap comentari:

Publica un comentari a l'entrada